B. Riley Cuts Earnings Estimates for Bicycle Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC) – Investment analysts at B. Riley dropped their FY2025 earnings per share estimates for Bicycle Therapeutics in a research report issued to clients and investors on Monday, March 3rd. B. Riley analyst K. Patel now forecasts that the company will post earnings per share of ($3.75) for the year, down from their prior forecast of ($3.70). B. Riley has a “Neutral” rating and a $17.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. B. Riley also issued estimates for Bicycle Therapeutics’ Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($4.34) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($3.92) EPS.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.10. The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s quarterly revenue was down 30.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.16) EPS.

A number of other equities research analysts have also recently weighed in on the stock. Stephens reissued an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. JMP Securities decreased their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Needham & Company LLC restated a “buy” rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Trading Up 2.6 %

Shares of NASDAQ:BCYC opened at $10.65 on Wednesday. The firm has a 50 day simple moving average of $12.93 and a 200-day simple moving average of $19.04. Bicycle Therapeutics has a twelve month low of $9.99 and a twelve month high of $28.67. The company has a market capitalization of $735.34 million, a PE ratio of -3.24 and a beta of 1.12.

Insiders Place Their Bets

In related news, insider Santiago Arroyo sold 4,943 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the sale, the insider now owns 69,057 shares in the company, valued at $973,013.13. This trade represents a 6.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $13.76 per share, for a total transaction of $13,559,062.72. Following the acquisition, the director now directly owns 9,537,643 shares in the company, valued at $131,237,967.68. This represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is owned by company insiders.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently modified their holdings of the business. FMR LLC purchased a new position in Bicycle Therapeutics in the third quarter worth $3,406,000. The Manufacturers Life Insurance Company grew its stake in shares of Bicycle Therapeutics by 33.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock worth $2,935,000 after purchasing an additional 32,313 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at about $10,028,000. State Street Corp lifted its stake in shares of Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after purchasing an additional 60,399 shares during the period. Finally, Jane Street Group LLC boosted its holdings in Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after buying an additional 5,310 shares in the last quarter. 86.15% of the stock is owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.